Generic Products

 ProductTherapeutic indicationEAN codeAlloga code
Carmustine Obvius powder and solvent for concentrate for solution for infusionAs a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery) for brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease and as a conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease/Non-Hodgkin’s lymphoma).
Carmustine Obvius 100mg powder
(1 x 1)
8719992196180USP4533
Dacarbazine powder for solution for injection/infusionFor the treatment of patients with metastasised malignant melanoma. Further indications as part of a combination chemotherapy are advanced Hodgkin's disease, advanced adult soft tissue sarcomas (except mesothelioma, Kaposi sarcoma).
Dacarbazine 100mg
(1 x 10)
40373533332227098494
Dacarbazine 200mg
(1 x 10)
40373533333217098502
Dacarbazine 500mg
(1 x 1)
40373533333387098510
Dacarbazine 1000mg
(1 x 1)
40373534333357098528
Doxorubicin Solution for InfusionSmall-cell lung cancer (SCLC), breast cancer, recurrent ovarian carcinoma, systemic treatment of local advanced or metastasized bladder carcinoma, intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection, neoadjuvant and adjuvant therapy of osteosarcoma, advanced soft-tissue sarcoma in adults, Ewing's sarcoma, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphatic leukaemia, acute myeloblastic leukaemia, advanced multiple myeloma, advanced or recurrent endometrial carcinoma, Wilms' tumour, advanced papillary/follicular thyroid cancer, anaplastic thyroid cancer, advanced neuroblastoma.
Doxorubicin solution 10mg/5ml
(1 x 1)
40373530059148364903
Doxorubicin solution 50mg/25ml
(1 x 1)
40373530059388364895
Doxorubicin solution 200mg/100ml
(1 x 1)
40373530059528364911
Epirubicin Solution for InjectionCarcinoma of the breast. advanced ovarian cancer, gastric cancer, small cell lung cancer. Administered intravesically in the treatment of papillary transitional cell carcinoma of the bladder, carcinoma-in-situ of the bladder, intravesical prophylaxis of recurrences of superficial bladder carcinoma following transurethral resection.
Epirubicin solution 10mg/5ml
(1 x 1)
40373530045428349078
Epirubicin solution 50mg/25ml
(1 x 1)
40373530045668349086
Epirubicin solution 200mg/100ml
(1 x 1)
40373530045808349094
Etoposide concentrate for solution for infusionTesticular cancer, small cell lung cancer, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, acute myeloid leukaemia, gestational trophoblastic neoplasia, ovarian cancer. platinum-resistant/refractory epithelial ovarian cancer in adults.
Etoposide solution 100mg/5ml
(1 x 1)
4037353017887USP0382
Etoposide solution 500mg/25ml
(1 x 1)
4037353017894USP9056
Fluorouracil 50mg/ml solution for injectionAlone or in combination for palliative management of common malignancies particularly cancer of the colon and breast, either as single agent or in combination with other cytotoxic agents.
Fluorouracil 500mg/10ml
(1 x 1)
40373539998868150997
Fluorouracil 1000mg/20ml
(1 x 1)
40373539999858151003
Fluorouracil 2500mg/50ml
(1 x 1)
40373539999928151011
Fluorouracil 5000mg/100ml
(1 x 1)
40373534433348151029
Fluorouracil 25mg/ml solution for injectionAlone or in combination for palliative management of common malignancies particularly cancer of the colon and breast, either as single agent or in combination with other cytotoxic agents.
Fluorouracil 2500mg/100ml
(1 x 1)
40373531222226806079
Hydroxycarbamide capsulesChronic myeloid leukaemia, cancer of the cervix in
conjunction with radiotherapy.
Hydroxycarbamide capsules 500mg
(1 x 100)
40373534444301106350
Irinotecan concentrate for solution for infusionAdvanced colorectal cancer as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen and in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
Irinotecan 40mg/2ml
(1 x 1)
40373530049558360448
Irinotecan 100mg/5ml
(1 x 1)
40373530049628356321
Irinotecan 300mg/15ml
(1x1)
40373530049798355208
Leflunomide tabletsActive rheumatoid arthritis as a "disease-modifying
antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomide 15mg tablets
(1 x 30)
4037353019546USP6171
Methotrexate solution for injectionAcute lymphocytic leukaemia, prophylaxis of meningeal
leukaemia, Non-Hodgkin's lymphomas, osteogenic
sarcoma, adjuvant and in advance disease of breast
cancer, metastatic or recurrent head and neck cancer,
choriocarcinoma and similar trophoblastic diseases,
advanced cancer of urinary bladder.
Methotrexate solution 1000mg/10ml
(1 x 1)
4037353017191USP5969
Methotrexate solution 5000mg/50ml
(1 x 1)
4037353017207USP5976
Oxaliplatin concentrate for solution for infusionIn combination with 5-fluorouracil (5-FU) and folinic acid (FA) for adjuvant treatment of stage III (Dukes' C) colon carcinoma after complete removal of the primary tumour, for the treatment of metastasising colorectal carcinoma.
Oxaliplatin 100mg/20ml
(1 x 1)
4037353008533USP9516
Oxaliplatin 200mg/40ml
(1 x 1)
4037353008540USP9509
Disodium folinate (Sodiofolin) solution for injection/infusionTo diminish the toxicity and counteract the action of folic acid antagonists such as methotrexate in cytotoxic therapy and overdose in adults and children.
Sodium folinate 100mg/2 ml
(1 x 1)
40373535444448151037
Sodium folinate 400mg/8 ml
(1 x 1)
40373531221168151045
Vinorelbine solution for infusionAs a single agent or in combination for the first line treatment of stage 3 or 4 non small cell lung cancer, advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.
Vinorelbine injection 10mg/1ml
(1x10)
40373530014118338162
Vinorelbine injection 50mg/5ml
(1x10)
40373530014358338154

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to medac drug safety at: drugsafety@medac.de

A PDF version of the Generic Product Listing is available to download.